natgillin/translations-raw huggingface dataset:
Your doctor will take this into account when treating your diabetes.
Vaš zdravnik bo to upošteval pri zdravljenju vaše sladkorne bolezni.
Although in very rare cases fatal outcome has been reported, causal relationship has not been established.
Čeprav so v zelo redkih primerih poročali o smrtnem izidu, vzročno razmerje ni bilo ugotovljeno.
Use in children and adolescents under 18 years is not recommended.
Uporabe zdravila pri otrocih in mladostnikih mlajših od 18 let ne priporočamo.
Your blood sugar could fall below the normal level and can be increased by taking sugar.
Vaš krvni sladkor lahko pade pod normalno raven in se lahko poveča z zaužitjem sladkorja.
Balkanpharma Dupnitsa AD 3 Samokovsko Shosse Str., Dupnitsa 2600, Bulgaria
Balkanpharma Dupnitsa AD 3 Samokovsko Shosse Str., Dupnitsa 2600, Bolgarija
This is the diabetes that usually develops in adulthood.
Ta vrsta sladkorne bolezni se običajno razvije v odrasli dobi.
- if you retain water (fluid retention) or have heart failure problems, in particular if you are over 75 years old.
- če zadržujete vodo (zastajanje tekočine v telesu) ali imate probleme s srčnim popuščanjem, zlasti če ste starejši od 75 let.
The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.
Najvišji poročani odmerek 120 mg/dan štiri dni, zatem pa 180 mg/dan sedem dni ni bil povezan s kakšnimi simptomi.
Do not take a double dose to make up for a forgotten tablet.
Ne vzemite dvojnega odmerka, da bi nadomestili izpuščeno tableto.
- if you have or have ever had bladder cancer.
- če imate ali ste imeli rak mehurja.
• Additional risk minimisation measures
Dodatni ukrepi za zmanjševanje tveganj
However patients who experience visual disturbance should be cautious when driving or using machines.
Vendar pa morajo biti bolniki, ki so imeli motnje vida, previdni pri vožnji ali upravljanju s stroji.
- if you have a problem with your liver or heart.
- če imate težave z jetri ali s srcem.
Your doctor will advise you to discontinue this medicine.
Zdravnik vam bo svetoval, da prenehate z jemanjem tega zdravila.
not known not known not known not known not known
neznana neznana neznana neznana neznana
In particular, patients have experienced the following serious side effects:
Konkretno so bili pri pacientih opaženi naslednji resnejši neželeni učinki:
Patients should be advised to adhere strictly to a calorie-controlled diet.
Bolnikom je treba svetovati, da se strogo držijo kalorijsko kontrolirane diete.
Your doctor will check whether Pioglitazone Teva is working 3 to 6 months after you start taking it.
Zdravnik bo preveril, ali zdravilo Pioglitazone Teva deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
The safety and efficacy of pioglitazone in children and adolescents under 18 years of age have not been established.
Varnost in učinkovitost pioglitazona pri otrocih in mladostnikih, mlajših od 18 let, ni potrjena.
You may take your tablets with or without food.
Tablete lahko zaužijete s hrano ali brez nje.
Your doctor will tell you the dose to take.
Zdravnik vam bo predpisal odmerek, ki ga morate jemati.
You may also experience a reduction in blood count (anaemia).
Prav tako lahko pride do zmanjšanja števila krvnih celic (anemija).
The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.
Pomena za ljudi glede tumorogenih ugotovitev pri samcih podgan, ni mogoče izključiti.
This medicine will not affect your ability to drive or use machines but take care if you experience abnormal vision.
To zdravilo ne bo vplivalo na vašo sposobnost vožnje ali upravljanja strojev, vendar bodite pozorni če imate motnje vida.
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).
Pioglitazon in vsi aktivni presnovki se v veliki meri vežejo na plazemske beljakovine (> 99 %).
This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.
Ta študija je pokazala povečanje poročil srčnega popuščanja, vendar to ni vodilo k dvigu smrtnosti v tej študiji.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali, ali pa boste morda začeli jemati katero koli drugo zdravilo.
Part of the treatment of diabetes is dietary control.
Del zdravljenja sladkorne bolezni je kontrola prehrane.
Your blood sugar will be checked, and your dose of Pioglitazone Teva may need to be changed.
Preverili bodo raven vašega krvnega sladkorja in vaš odmerek zdravila Pioglitazon Teva bo morda potrebno spremeniti.
Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke.
Skoraj polovica bolnikov je predhodno doživela miokardni infarkt in približno 20 % je doživelo kap.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2-5 %.
Many of these patients reported concurrent peripheral oedema.
Mnogo teh bolnikov je poročalo o sočasnem perifernem edemu.
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Skoraj vse osebe (95 %) so prejemale kardiovaskularna zdravila (beta blokatorje, ACE inhibitorje, antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, aspirin, statine, fibrate),
The European Medicines Agency has waived the obligation to submit the results of studies with pioglitazone in all subsets of the paediatric population in Type 2 Diabetes Mellitus.
Evropska agencija za zdravila je opustila obveznost predložitve rezultatov študij z pioglitazonom pri vseh podskupinah pediatrične populacije z diabetesom tipa 2.
- if you have heart failure or have had heart failure in the past.
- če imate srčno popuščanje ali ste imeli srčno popuščanje v preteklosti.
The relevance of such a mechanism in humans is unclear and pioglitazone should not be used in pregnancy.
Pomen takega mehanizma pri ljudeh ni jasen, pioglitazona pa se med nosečnostjo ne sme uporabljati.
Pioglitazone tablets are taken orally once daily with or without food.
Tablete, ki vsebujejo pioglitazon se jemljejo peroralno enkrat dnevno s hrano ali brez nje.
- if you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).
- če imate poseben tip diabetične očesne bolezni imenovane makularni edem (oteklina očesnega ozadja).
Pioglitazone Teva has no or negligible influence on the ability to drive and use machines.
Zdravilo Pioglitazon Teva nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Pioglitazone Teva helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.
Zdravilo Pioglitazon Teva pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.
Če imate resno alergijsko reakcijo, ki vključuje koprivnico in otekanje obraza, ustnic, jezika ali grla, ki lahko povzroča težave z dihanjem ali požiranjem, takoj prenehajte z jemanjem tega zdravila in se nemudoma pogovorite s svojim zdravnikom.
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.
Ni jasno ali obstaja neposredna povezava med pioglitazonom in makularnim edemom, vendar pa morajo biti zdravniki pozorni na možnost makularnega edema, če bolnik poroča o motnjah vidne ostrine; upoštevati je treba ustrezno oftamolmološko mnenje.
This is similar to that seen in a sulphonylurea active comparator group.
To je podobno opažanjem v primerjalni skupini s sulfonilsečnino.
If ALT levels remain > 3 X the upper limit of normal, therapy should be discontinued.
Če ravni ALT ostanejo > 3-kratne zgornje meje normalnih vrednosti, je treba zdravljenje prekiniti.
In some cases weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored.
V nekaterih primerih je povečanje telesne mase lahko simptom srčnega popuščanja, zato je treba telesno maso skrbno spremljati.
- if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
- če ste preobčutljivi na pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju
In light of age- related risks (especially bladder cancer, fractures and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.
Glede na s starostjo povezana tveganja (zlasti rak mehurja, zlomi in srčno popuščanje), je treba pri starejših ravnovesje med koristmi in tveganji skrbno pretehtati pred in med zdravljenjem.
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone.
Opazili so večje število zlomov kosti še zlasti pri ženskah, ki so jemale pioglitazon.
Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Interakcij s snovmi, ki jih presnavljajo ti encimi, npr. s peroralnimi kontracepcijskimi sredstvi, ciklosporinom, zaviralci kalcijevih kanalčkov in inhibitorji HMGCoA reduktaze, ni pričakovati.
If patients report hypoglycaemia, the dose of insulin should be decreased.
Če bolniki poročajo o hipoglikemiji, je treba odmerek insulina znižati.
As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual or triple oral therapy with a sulphonylurea or in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.
Kot posledica povečane občutljivosti na insulin, so lahko bolniki, ki prejemajo pioglitazon v dvojnem ali trojnem zdravljenju s sulfonilsečnino ali v dvojnem zdravljenju z insulinom, izpostavljeni tveganju za od odmerka odvisno hipoglikemijo, in je morda potrebno znižati odmerek sulfonilsečnine ali insulina.
If you have the impression that the effect of Pioglitazone Teva is too weak, talk to your doctor.
Če menite, da je učinek zdravila Pioglitazon Teva prešibak, se posvetujte z zdravnikom.
If you take Pioglitazone Teva with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).
Če ste vzeli zdravilo Pioglitazon Teva z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost vašega krvnega sladkorja pade pod normalno raven (hipoglikemija).
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva.
Običajno lahko še naprej jemljete druga zdravila medtem ko se zdravite z zdravilom Pioglitazon Teva.
Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%).
Izločanje Po peroralnem dajanju radioaktivno označenega pioglitazona človeku so označevalec zaznali predvsem v blatu (55 %) in manjšo količino v urinu (45 %).
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually.
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt ali simptomatska koronarna arterijska bolezen), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
- if you have liver disease.
- če imate obolenje jeter.
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: zelo pogosti (≥1/10) ; pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Pioglitazone Teva with food and drink
Zdravilo Pioglitazon Teva skupaj s hrano in pijačo
When Pioglitazone Teva is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.
Če boste jemali zdravilo Pioglitazon Teva skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
These findings were observed across species at plasma concentrations ≤ 4 times the clinical exposure.
Te ugotovitve so potrdila opažanja pri vseh vrstah pri plazemskih koncentracijah ≤ 4-kratne plazemske koncentracije pri klinični izpostavitvi.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03.
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, antidiabetiki; oznaka ATC: A10BG03.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
O primerih raka mehurja so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12506 bolnikov, 0,15 %) kot v kontrolnih skupinah (7 primerov od 10212 bolnikov, 0,07 %) HR = 2,64 (95 % IZ 1,11-6,31, P = 0,029).
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
5 O edemih so poročali pri 6-9 % bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema).
Simptomi so nenavadno težko dihanje ali hitro povečanje telesne mase ali lokalne otekline (edemi).
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
Priporočljivo je, da imat pri sebi nekaj kock sladkorja, bonbone,
Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily.
Zdravljenje s pioglitazonom lahko začnemo s 15 mg ali 30 mg enkrat dnevno.
There are no adequate human data to determine the safety of pioglitazone during pregnancy.
Za ugotavljanje varnosti pioglitazona med nosečnostjo ni zadostnih podatkov iz preskušanj pri človeku.
These effects were independent of pioglitazone's effects on glycaemia and were statistically significantly different to glibenclamide.
Ti učinki niso bili odvisni od pioglitazonovih učinkov na glikemijo in so se statistično značilno razlikovali od glibenklamida.
Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region).
Dejavnike tveganja za rak mehurja je treba oceniti pred začetkom zdravljenja s pioglitazonom (tveganja vključujejo starost, kajenje v anamnezi, izpostavljenost nekaterim poklicnim dejavnikom ali kemoterapiji npr. ciklofosfamidu ali zdravljenje pred obsevanjem v predelu medenice).
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups.
Ko so izločili bolnike, ki so bili v času diagnoze rak mehurja preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06 %) raka mehurja pri pioglitazonu in 2 primera (0,02 %) v kontrolnih skupinah.
Brampton Road, Hampden Park, Eastbourne, East Sussex - BN22 9AG United Kingdom
Brampton Road, Hampden Park, Eastbourne East Sussex - BN22 9AG Velika Britanija
Your doctor may increase the dose to a maximum of 45 mg once a day.
Zdravnik vam lahko poveča odmerek do največ 45 mg enkrat na dan.
This medicine does not require any special storage precautions.
Za shranjevanje zdravila niso potrebna posebna navodila.
31-546, Krakow Poland
Mogilska 80. 31-546, Krakow Poland
At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
Po dveh letih je nadzor glikemije (definiran kot HbA1c < 8,0 %) vztrajal pri 69 % bolnikov, zdravljenih s pioglitazonom, v primerjavi s 50 % bolnikov, ki so prejemali gliklazid.
See section 4.2 for information on paediatric use.
Za informacije o pediatrični uporabi glejte poglavje 4.2.
Close monitoring of glycaemic control should be considered (see section 4.4).
Pretehtati je potrebno skrbno spremljanje glikemičnega nadzora (glejte poglavje 4.4).
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.
2 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenju z drugimi hipoglikemiki.
Before you start taking Pioglitazone Teva you will have a blood sample taken to check your liver function.
Pred začetkom jemanja zdravila Pioglitazon Teva vam bodo odvzeli vzorec krvi, da se preveri delovanje vaših jeter.
Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.
V vsaki skupini organskih sistemov so neželeni učinki navedeni po padajoči pogostnosti in padajoči resnosti.
What Pioglitazone Teva is and what it is used for
Kaj je zdravilo Pioglitazon Teva in za kaj ga uporabljamo
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree.
Ta poteka predvsem prek citokromov P450 2C8, v manjši meri pa so lahko vpletene tudi druge izooblike.
If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible.
Če se med zdravljenjem s pioglitazonom ravni ALT zvišajo do 3-kratne zgornje meje normalnih vrednosti, je treba ravni jetrnih encimov čimprej ponovno kontrolirati.
OTHER (FOR CALENDARISED PACKS)
DRUGI PODATKI (OKRAJŠAVE ZA DNI V TEDNU ZA KOLEDARSKA PAKIRANJA)
What you need to know before you take Pioglitazone Teva Do not take Pioglitazone Teva
Kaj morate vedeti, preden boste vzeli zdravilo Pioglitazon Teva Ne jemljite zdravila Pioglitazon Teva
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45 % v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini zdravljeni s pioglitazonom.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva.
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Pioglitazon Teva.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
Izračunana incidenca zlomov je bila 1,9 zlomov na 100 bolniških let pri ženskah, zdravljenih s pioglitazonom in 1,1 zlomov na 100 bolniških let pri ženskah, zdravljenih s primerjalnim zdravilom.
Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration.
Absorpcija Po peroralnem dajanju se pioglitazon hitro absorbira, maksimalne plazemske koncentracije nespremenjenega pioglitazona so običajno dosežene 2 uri po dajanju.
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070
ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070
Pioglitazone has been shown to be present in the milk of lactating rats.
Pioglitazon so dokazali v mleku doječih podgan.
To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease.
Da bi bolniki ustrezali kriterijem, so morali imeti v anamnezi eno ali več od sledečega: miokardni infarkt, kap, perkutano srčno intervencijo ali koronarni arterijski transplantatni obvod, akutni koronarni sindrom, koronarno arterijsko bolezen ali periferno arterijsko obstrukcijsko bolezen.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinek pioglitazona (45 mg monoterapija v primerjavi s placebom) so preučevali v majhnem 18tedenskem preskušanju pri diabetikih tipa 2.
- The tablets are supplied in blisters in packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets.
- Tablete so na voljo v pretisnih omotih v pakiranjih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet.
In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.
V enoletnih kliničnih preskušanjih je pioglitazon vedno statistično značilno znižal razmerje albumin/kreatinin v primerjavi z izhodiščnimi vrednostmi.
No information is available from dialysed patients therefore pioglitazone should not be used in such patients.
Podatkov o uporabi pioglitazona pri bolnikih na dializi ni, zato ga pri takih bolnikih ne smemo uporabljati.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin.
V študiji izida bolnikov z že obstoječimi težjimi makrovaskularnimi boleznimi, je bila incidenca resnega srčnega popuščanja 1,6 % višja s pioglitazonom kot s placebom, dodanim k zdravljenju, ki je vključevalo insulin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.
Študije medsebojnih delovanj so pokazale, da pioglitazon nima pomembnega učinka na farmakokinetiko ali farmakodinamiko digoksina, varfarina, fenprokumona in metformina.
General disorders and administration site conditions oedema5
Splošne težave in spremembe na mestu aplikacije edem5
• The risk of bladder cancer risk and relevant risk minimisation advice.
• Tveganje za nastanek raka mehurja in ustrezen nasvet za zmanjšanje tveganja.
Fertility In animal fertility studies there was no effect on copulation, impregnation or fertility index.
Plodnost V študijah plodnosti pri živalih ni bilo vpliva na parjenje, oploditev ali rodnost.
No dose adjustment is necessary for elderly patients (see section 5.2).
Pri starejših bolnikih odmerka ni treba prilagajati (glejte poglavje 5.2).